Marcus Lindberg

Marcus Lindberg

Auto-generated profile, based on publicly available information

Marcus Lindberg

Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, Scotland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2019 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ACAude G. Chapuis
Aude G. Chapuis
DEDaniel N. Egan
Daniel N. Egan
MBMerav Bar
Merav Bar
TSThomas M. Schmitt
Thomas M. Schmitt
MMMegan S. McAfee
Megan S. McAfee
PGPhilip D. Greenberg
Philip D. Greenberg
Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features1,2,3. When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells4. As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versus-host disease5. Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens6. We therefore isolated a high-affinity Wilms’ Tumor Antigen 1-specific TCR (TCRC4) from HLA-A2+ normal donor repertoires, inserted TCRC4 into Epstein–Bar virus-specific donor CD8+ T cells (TTCR-C4) to minimize graft-versus-host disease risk and enhance transferred T cell survival7,8, and infused these cells prophylactically post-HCT into 12 patients (NCT01640301). Relapse-free survival was 100% at a median of 44 months following infusion, while a concurrent comparative group of 88 patients with similar risk AML had 54% relapse-free survival (P = 0.002). TTCR-C4 maintained TCRC4 expression, persisted long-term and were polyfunctional. This strategy appears promising for preventing AML recurrence in individuals at increased risk of post-HCT relapse.

2 December 2020 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
KBKaterina Boufea
Katerina Boufea
VHVictor Gonzalez Huici
Victor Gonzalez Huici
MLMarcus Lindberg
Marcus Lindberg
SSStefan Symeonides
Stefan Symeonides
OOOlga Oikonomidou
Olga Oikonomidou
NBNizar N Batada
Nizar N Batada
The association of increased levels of tumour-infiltrating gamma-delta (γδ) T cells with favorable prognosis across many cancer types and their ability to recognize stress antigens in an MHC unrestricted manner has led to an increased interest in exploiting them for cancer immunotherapy. We performed single-cell RNA sequencing (scRNA-seq) of peripheral blood γδ T cells from healthy adult donors and from fresh tumour biopsies of breast cancer patients. We identified five γδ T cells subtypes in blood and three subtypes of γδ T cells in breast tumour. These subtypes differed in the expression of genes contributing to effector functions such as antigen presentation, cytotoxicity, and IL17A and IFNγ production. Compared with the blood γδ T cells, the breast tumour-infiltrating γδ T cells were more activated, expressed higher levels of cytotoxic genes, yet were immunosuppressed. One subtype in the breast tumour that was IFNγ-positive had no obvious similarity to any of the subtypes observed in the blood γδ T cell and was the only subtype associated with improved overall survival of breast cancer patients. Taken together, our study has identified markers of subtypes of human blood γδ T cells and uncovered a tumour-infiltrating γδ T cells subtype associated improved overall cancer survival.

13 December 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
KBKaterina Boufea
Katerina Boufea
VHVictor Gonzalez Huici
Victor Gonzalez Huici
MLMarcus Lindberg
Marcus Lindberg
NONelly N Olova
Nelly N Olova
SSStefan Symeonides
Stefan Symeonides
NBNizar N Batada
Nizar N Batada
Single cell sequencing of γδ-T cells from human blood and tumours revealed novel markers of subtypes with distinct effector functions and a subtype that is associated with favourable clinical outcome.